Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  51,253 results for ""NATALIZUMAB""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.

  • Authors : Carotenuto A; Department of Neuroscience, Reproductive Science and Odontostomatology, Multiple Sclerosis Clinical Care and Research Centre, Federico II University, Naples, Italy. .; Di Monaco C

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/therapeutic use ; Fingolimod Hydrochloride*/Fingolimod Hydrochloride*/Fingolimod Hydrochloride*/therapeutic use ; Immunologic Factors*/Immunologic Factors*/Immunologic Factors*/administration & dosage

  • Source: Journal of neurology [J Neurol] 2024 Oct; Vol. 271 (10), pp. 6773-6781. Date of Electronic Publication: 2024 Aug 23.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.

  • Authors : Gelissen LMY; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology Outpatient Clinic, De Boelelaan 1118, Amsterdam 1081 HV, the Netherlands. Electronic address: .; Loveless S

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/administration & dosage ; Natalizumab*/Natalizumab*/Natalizumab*/blood ; Immunologic Factors*/Immunologic Factors*/Immunologic Factors*/administration & dosage

  • Source: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Oct; Vol. 90, pp. 105796. Date of Electronic Publication: 2024 Jul 30.Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.

  • Authors : Foley JF; From the Rocky Mountain MS Clinic (J.F.F.), Salt Lake City, UT; Department of Neurology (G.D.), Centre Hospitalier Universitaire de Caen, France

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/administration & dosage ; Natalizumab*/Natalizumab*/Natalizumab*/pharmacokinetics ; Natalizumab*/Natalizumab*/Natalizumab*/pharmacology

  • Source: Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2024 Dec; Vol. 11 (6), pp. e200321. Date of Electronic Publication: 2024 Oct 11.Publisher: Wolters Kluwer Health/Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101636388 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.

  • Authors : Toorop AA; Department of Neurology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Wessels MH

Subjects: Neurofilament Proteins*/Neurofilament Proteins*/Neurofilament Proteins*/blood ; Natalizumab*/Natalizumab*/Natalizumab*/adverse effects ; Glial Fibrillary Acidic Protein*/Glial Fibrillary Acidic Protein*/Glial Fibrillary Acidic Protein*/blood

  • Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Nov; Vol. 30 (13), pp. 1683-1688. Date of Electronic Publication: 2024 Nov 04.Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.

  • Authors : Selmaj K; Department of Neurology, Center of Neurology, University of Warmia & Mazury, Olsztyn, Lodz, Poland.; Roth K

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/therapeutic use ; Natalizumab*/Natalizumab*/Natalizumab*/pharmacology ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use

  • Source: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2024 Nov; Vol. 38 (6), pp. 755-767. Date of Electronic Publication: 2024 Sep 30.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9705305 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.

  • Authors : Clarelli F; Laboratory of Human Genetics of Neurological Disorders, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.; Corona A

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/therapeutic use ; Genome-Wide Association Study* ; Polymorphism, Single Nucleotide*

  • Source: Journal of neurology [J Neurol] 2024 Nov; Vol. 271 (11), pp. 7250-7263. Date of Electronic Publication: 2024 Sep 12.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: A post-hoc analysis of the REFINE study.

  • Authors : Mariottini A; Department of NEUROFARBA, University of Florence, Florence, Italy; Department of Neurology 2 and Tuscan Region Multiple Sclerosis Referral Centre, Careggi University Hospital, Florence, Italy. Electronic address: .

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/administration & dosage ; Multiple Sclerosis, Relapsing-Remitting*/Multiple Sclerosis, Relapsing-Remitting*/Multiple Sclerosis, Relapsing-Remitting*/drug therapy ; Multiple Sclerosis, Relapsing-Remitting*/Multiple Sclerosis, Relapsing-Remitting*/Multiple Sclerosis, Relapsing-Remitting*/diagnostic imaging

  • Source: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Nov; Vol. 91, pp. 105852. Date of Electronic Publication: 2024 Aug 27.Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Report

Concurrent management of multiple sclerosis and natalizumab-induced hepatitis with ofatumumab: a case report.

  • Authors : Haggiag S; Department of Neuroscience, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy. .; Giannelli V

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/adverse effects ; Natalizumab*/Natalizumab*/Natalizumab*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects

  • Source: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2024 Oct; Vol. 45 (10), pp. 5087-5089. Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100959175 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres.

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/adverse effects ; JC Virus*/JC Virus*/JC Virus*/immunology ; Antibodies, Viral*/Antibodies, Viral*/Antibodies, Viral*/blood

  • Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Oct; Vol. 30 (11-12), pp. 1561-1565. Date of Electronic Publication: 2024 Jun 14.Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.

  • Authors : Yokote H; From the Department of Neurology (H.Y., T.M., Y.M.), Tokyo Metropolitan Komagome Hospital; Department of Neurology and Neurological Science (H.Y.), Tokyo Medical and Dental University

Subjects: Natalizumab*/Natalizumab*/Natalizumab*/adverse effects ; Immune Reconstitution Inflammatory Syndrome*/Immune Reconstitution Inflammatory Syndrome*/Immune Reconstitution Inflammatory Syndrome*/chemically induced ; Leukoencephalopathy, Progressive Multifocal*/Leukoencephalopathy, Progressive Multifocal*/Leukoencephalopathy, Progressive Multifocal*/diagnostic imaging

  • Source: Neurology [Neurology] 2024 Oct 08; Vol. 103 (7), pp. e209874. Date of Electronic Publication: 2024 Aug 30.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  51,253 results for ""NATALIZUMAB""